Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome

International Journal of Clinical Oncology

Volumn 12, Issue 1, 2007, Pages 59-62

  Sano, Takeshi ^a   Sakai, Hisashi ^a   Takimoto, Kengo ^a   Ohno, Hitoshi ^a  

^a TAKEDA GENERAL HOSPITAL   (Japan)

Author keywords

Antibody dependent cellular toxicity; Diffuse large B cell lymphoma; Hemophagocytic syndrome; Rituximab

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; METHYLPREDNISOLONE; OMEPRAZOLE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADRENAL GLAND; ADULT; ARTICLE; B CELL LYMPHOMA; BONE MARROW; CANCER THERAPY; CASE REPORT; DISEASE ASSOCIATION; ERYTHROPHAGOCYTOSIS; GASTRIC ULCER BLEEDING; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOPHENOTYPING; LABORATORY TEST; MALE; MONOTHERAPY; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; RESUSCITATION; SPLEEN; STOMACH HEMORRHAGE; TREATMENT RESPONSE;

ABDOMINAL NEOPLASMS; ADRENAL GLAND NEOPLASMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHATIC METASTASIS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; SPLENIC NEOPLASMS; TRANSCRIPTION FACTOR CHOP;

EID: 33947537946     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0627-9     Document Type: Article

References (13)

1. C Shimazaki T Inaba M Nakagawa 2000 B-cell lymphoma-associated hemophagocytic syndrome Leuk Lymphoma 38 121 130
2. T Murase S Nakamura K Tashiro 1997 Malignant histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis: a report of five cases and review of the literature Br J Haematol 99 656 664
3. K Tobinai 2002 Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan Int J Hematol 76 411 419
4. K Tobinai T Igarashi K Itoh 2004 Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma Ann Oncol 15 821 830
5. JM Vose BK Link ML Grossbard 2001 Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19 389 397
6. WP Schmidt N Schmitz R Sonnen 2004 Conservative management of gastric lymphoma: the treatment option of choice Leuk Lymphoma 45 1847 1852
7. RA Popescu AC Wotherspoon D Cunningham 1999 Surgery plus chemotherapy or chemotherapy alone for primary intermediate- and high-grade gastric non-Hodgkin's lymphoma: the Royal Marsden Hospital experience Eur J Cancer 35 928 934
8. DG Maloney TM Liles DK Czerwinski 1994 Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 84 2457 2466
9. D Shan JA Ledbetter OW Press 1998 Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91 1644 1652
10. T Ohno Y Ueda K Nagai 2003 The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas Int J Hematol 77 286 294
11. LE van der Kolk AJ Grillo-Lopez JW Baars 2003 Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy Leukemia 17 1658 1664
12. M Yamaguchi M Seto M Okamoto 2002 De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients Blood 99 815 821
13. HS Khalidi RK Brynes P Browne 1998 Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases Mod Pathol 11 983 988